Phase 1 Study of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors

June 1, 2022

American Society of Clinical Oncology (ASCO) 2022 Annual Meeting

STAT3_ASCO_ThumbNail
Area of Focus
Oncology
Programs
STAT3 (KT-333)
Indications
CTCL LGL-L PTCL Solid Tumors
Development Stage
Clinical Data
Share
LinkedInXFacebookEmailCopy Link